Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
Salvetti M, Wray S, Nelles G, Altincatal A, Kumar A, Koster T, Naylor ML; Plegridy Observational Program investigators. Salvetti M, et al. Among authors: altincatal a. Mult Scler Relat Disord. 2022 Jan;57:103350. doi: 10.1016/j.msard.2021.103350. Epub 2021 Oct 29. Mult Scler Relat Disord. 2022. PMID: 35158459 Free article.
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD, Scott TF, Arnold DL, Altincatal A, Naylor ML. Newsome SD, et al. Among authors: altincatal a. Mult Scler Relat Disord. 2022 Jan;57:103367. doi: 10.1016/j.msard.2021.103367. Epub 2021 Nov 3. Mult Scler Relat Disord. 2022. PMID: 35158473 Free article. Clinical Trial.
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C. Reder AT, et al. Among authors: altincatal a. CNS Drugs. 2021 Mar;35(3):317-330. doi: 10.1007/s40263-021-00804-1. Epub 2021 Mar 20. CNS Drugs. 2021. PMID: 33743151 Free PMC article.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
Hersh CM, Altincatal A, Belviso N, Kapadia S, de Moor C, Rudick R, Williams JR, Miller C, Koulinska I. Hersh CM, et al. Among authors: altincatal a. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35024161 Free PMC article.
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Santini V, Almeida A, Giagounidis A, Platzbecker U, Buckstein R, Beach CL, Guo S, Altincatal A, Wu C, Fenaux P. Santini V, et al. Among authors: altincatal a. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):136-144.e7. doi: 10.1016/j.clml.2017.12.004. Epub 2017 Dec 30. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29429612 Free article. Clinical Trial.
52 results